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Abstract We compared the anti-HIV-1 activity of CC-chemo-
kine LD78L with that of MIP-1K, another CC-chemokine which
shows 94% sequence homology with LD78L. Despite its close
similarity to MIP-1K, the anti-HIV-1 activity of LD78L
appeared to be nearly 10 times higher than that of MIP-1K.
Mutagenesis of MIP-1K showed that the N-terminal additional
tetrapeptide, which was present in LD78L and absent in MIP-1K,
is responsible for enhanced anti-HIV-1 activity. The N-terminal
structure-function relationship of LD78L described here will be
of value in understanding the chemokine-receptor interactions
and designing anti-HIV-1 compounds based on LD78L.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Chemokines constitute a large family of small chemotactic
cytokines of 60^80 amino acid residues. There are two major
subfamilies of chemokines, CC-chemokines and CXC-chemo-
kines, which di¡er in their spacing of the ¢rst two cysteine
residues [1,2]. Two exceptions to the CC/CXC rule have been
reported: one is a C-chemokine, lymphotactin, and another is
a CX3C-chemokine, fractalkine [1,2]. Recently, some of the
receptors of CC-chemokines and CXC-chemokines were
proved to serve as essential coreceptors for cellular entry of
human immunode¢ciency virus type 1 (HIV-1) [3^9]. Corecep-
tor usage by HIV-1 is strain-speci¢c. For instance, macro-
phage tropic/non-syncytium-inducing strains use CC-chemo-
kine receptor 5 (CCR5) for their entry into cells [3,5^8]. On
the other hand, CXC-chemokine receptor 4 (CXCR4) serves
as a coreceptor for T-cell line tropic/syncytium-inducing
strains [4,9].
MIP-1K (macrophage in£ammatory peptide 1K), also re-
ferred to as LD78K, is one of the natural ligands of CCR5,
and is able to induce chemotaxis of many mature leukocyte
types [1,2]. MIP-1K strongly inhibits proliferation of hemato-
poietic stem cells [10,11] and moderately suppresses in vitro
replication of macrophage tropic strains of HIV-1, which use
CCR5 as a coreceptor [12]. LD78L, a non-allelic variant of
MIP-1K, shows more than 94% sequence homology with
MIP-1K [13,14]. Despite its close similarity to MIP-1K, bio-
logical activities of LD78L on HIV-1 infection have not been
fully clari¢ed yet. In this report, we demonstrate that recombi-
nant LD78L expressed in mammalian cells by Sendai virus
(SeV) vector [15,16,17] is able to suppress replication of mac-
rophage tropic strains of HIV-1 10 times more e⁄ciently than
recombinant MIP-1K. The N-terminal tetrapeptide of LD78L,
which is absent in MIP-1K, appears to be responsible for the
elevated anti-HIV-1 activity.
2. Materials and methods
2.1. Cells and virus
Human peripheral blood mononuclear cells (PBMC) obtained from
healthy volunteers (Japanese Red Cross Central Blood Center) were
isolated by Ficoll/Hypaque gradient centrifugation. CD4+ cells were
puri¢ed from the PBMC with magnetic beads coated with anti-CD4
antibody as described previously [18]. Monkey kidney CV1 cells were
grown in minimum essential medium (MEM) supplemented with 10%
fetal bovine serum (FBS). HIV-1 strain SF162 was propagated in
phytohemagglutinin (PHA)-stimulated PBMC which were maintained
in RPMI 1640 containing 32 U/ml human interleukin-2 (IL-2, Boeh-
ringer Mannheim, Germany) and 10% FBS.
2.2. Generation of recombinant SeV
MIP-1K cDNA was cloned from PHA and 12-myristate 13-acetate-
stimulated PBMC by nested RT-PCR. LD78L and its mutant genes
were generated by site-directed mutagenesis by using two or three
successive PCRs using MIP-1K cDNA as a template. All PCRs were
performed with ExTaq DNA polymerase (Takara, Kyoto, Japan),
and all the PCR products were veri¢ed for their sequence authenticity.
Recombinant SeV carrying MIP-1K, LD78L and their derivatives were
generated according to the method described previously [15^17,19].
2.3. Production of human MIP-1K, LD78L and their derivatives
CV1 cells were infected with recombinant SeV expressing MIP-1K,
LD78L, or their derivatives at 10 plaque-forming units (PFU) per cell.
Seventy-two hours after infection, serum-free culture supernatants
were harvested and centrifuged at 48,000Ug for 2 h at 4‡C. The
amount of MIP-1K and its derivatives in the culture supernatant
was determined by Human MIP-1K Immunoassay Kit (RpD, USA).
2.4. Western blotting
The culture supernatant of infected cells was electrophoresed in
15% polyacrylamide gels (Mini-Protean II Ready Gels J, Bio-Rad).
The proteins in the gels were electrotransferred onto polyvinylidene
di£uoride (PVDF) membranes (Millipore, Bedford, MA, USA) at 100
mA for 1 h and probed with anti-MIP-1K antibody (Genzyme, USA).
2.5. CD26-mediated cleavage of LD78L
Murine ¢broblast L cells expressing CD26 [20] were infected with
recombinant SeV expressing LD78L at 30 PFU per cell and main-
tained in serum-free Dulbecco’s modi¢ed Eagle’s medium (DMEM)
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for 72 h. LD78L in the culture supernatants was analyzed by Western
blotting and N-terminal peptide sequencing (Takara, Kyoto, Japan).
2.6. Anti-HIV-1 assay
PBMC obtained from healthy donors (1.5U106/ml) were stimulated
with PHA for 3 days and exposed to the macrophage tropic HIV-1
strain SF162 equivalent to 12 ng of p24 antigen for 2 h at 37‡C. The
cells were washed three times and then maintained in the medium
described above in the presence of indicated concentrations of
LD78-derived chemokines. The culture supernatants were harvested
3 days after infection and assayed for the levels of p24 core antigen
(Abbott, Wiesbaden-Delkenheim, Germany).
2.7. Competitive binding assay of LD78L
Receptor binding activity of LD78-derived chemokines was assayed
by competitive binding of these chemokines with 125I-labeled MIP-1K
to puri¢ed CD4+ cells. We modi¢ed a protocol originally described
by Haribabu et al. [21]. Brie£y, 2U106 PHA-stimulated CD4+ cells
were incubated in 200 Wl of DMEM containing 25 mM HEPES, 1%
BSA, 1 nM of 125I-labeled MIP-1K (0.25 mCi, NEN Life Science
Products, Boston, MA, USA) and increasing concentrations of unla-
beled LD78-derived chemokines. After incubation for 2 h, the cells
were washed twice with DMEM containing 25 mM HEPES and 1%
BSA and cell-bound radioactivity was counted on a 1470 WIZARD
Gamma Counter (Wallac, USA). Inhibition of binding of 125I-labeled
MIP-1K was determined by the formula (An3Bn)100%/An, where An
is the cpm bound in the absence of any competitors; Bn is the cpm
bound in the presence of indicated concentration of competitors.
3. Results
3.1. Expression of MIP-1K and LD78L by a SeV vector
Four to ¢ve Wg/ml of MIP-1K was detected in the culture
supernatant of CV1 cells infected with the recombinant SeV
carrying the human MIP-1K gene. A similar level of LD78L
was detected in the culture supernatant of CV1 cells infected
with the SeV carrying the LD78L gene (Fig. 1A). The N-ter-
minal sequence analysis of recombinant MIP-1K revealed a
pentapeptide, ADTPT, in its N-terminus (Fig. 1A,B), instead
of the tetrapeptide ASLA which was previously suggested to
be present at the N-terminus of mature MIP-1K [13]. In con-
trast, the N-terminal tetrapeptide APLA was fully retained in
recombinant LD78L (Fig. 1A,B). Therefore, mature MIP-1K
appears to be composed of 66 amino acids, whereas mature
LD78L consists of 70 amino acids.
3.2. Anti-HIV-1 and receptor binding activities of MIP-1K and
LD78L
Recombinant MIP-1K and LD78L were assayed for their
anti-HIV-1 activity. As shown in Fig. 2, MIP-1K suppressed
90% of p24 production of HIV-1 macrophage tropic strain
SF162 in PBMC culture at a concentration of 300 ng/ml. In
contrast, LD78L suppressed more than 99% of p24 produc-
tion at a concentration of 300 ng/ml and suppressed 90% of
p24 production even at a concentration of 15 ng/ml. These
data clearly indicate that LD78L is a more potent anti-HIV-1
suppressor than MIP-1K.
To evaluate binding a⁄nity of MIP-1K and LD78L to their
receptors, we performed competitive binding assays of MIP-
1K and LD78L to CD4+ cells with 125I-labeled MIP-1K (Fig.
3). 70 ng/ml of MIP-1K was required for 50% inhibition of
radiolabeled MIP-1K binding, while 20 ng/ml of LD78L was
su⁄cient for 50% inhibition, indicating that LD78L has higher
receptor binding a⁄nity than MIP-1K.
3.3. The N-terminal tetrapeptide APLA is responsible for
enhanced anti-HIV-1 and receptor binding activities of
LD78L
Except for the N-terminal tetrapeptide, there are two amino
acid di¡erences between mature MIP-1K and LD78L (Fig.
1B). To test whether the N-terminal tetrapeptide APLA is
Fig. 1. Expression of MIP-1K, LD78L, LD78L-MIP-1K, and Met-
MIP-1K. A: Proteins in culture supernatants of CV-1 cells infected
with SeV carrying indicated chemokine genes or the wild type SeV
(SeV) were analyzed by SDS-polyacrylamide gel electrophoresis and
Western blotting using anti-MIP-1K antibody. M indicates protein
size markers. The position of a 6.5-kDa marker is shown by the ar-
row. The N-terminal amino acid sequence of each protein band is
shown. B: Alignment of amino acid sequences of MIP-1K, LD78L,
LD78L-MIP-1K, and Met-MIP-1K. Dashes indicate sequence iden-
tity.
Fig. 2. Anti-HIV-1 activity of MIP-1K (closed circles), LD78L
(closed triangles), LD78L-MIP-1K (open triangles), and Met-MIP-1K
(closed squares). Culture supernatants of CV-1 cells infected with
SeV carrying indicated chemokine genes or the wild type SeV (open
circles) were serially diluted and assayed for their anti-HIV-1 activ-
ity as described in Section 2. Data shown are representative of three
independent experiments with similar results.
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responsible for the elevated anti-HIV-1 and receptor binding
activity of LD78L, we constructed chimeric MIP-1K carrying
the N-terminal tetrapeptide APLA (LD78L-MIP-1K). We also
generated mutant MIP-1K carrying an additional methionine
residue at the N-terminus (Met-MIPK). The LD78L-MIP-1K
and Met-MIP-1K were expressed and secreted as e⁄ciently as
the wild type MIP-1K and LD78L into culture supernatant of
CV-1 cells infected with recombinant SeV carrying the respec-
tive mutant MIP-1K genes (Fig. 1A). The N-terminal amino
acid sequence analysis con¢rmed the presence of the tetrapep-
tide and a methionine residue in mature LD78L-MIP-1K and
Met-MIP-1K, respectively.
As shown in Fig. 2, the chimeric LD78L-MIP-1K sup-
pressed HIV-1 replication as e⁄ciently as did LD78L.
LD78L-MIP-1K also showed elevated binding a⁄nity to
CD4+ cells (Fig. 3). In contrast, anti-HIV-1 and receptor
binding activity of Met-MIP-1K was the same as for MIP-
1K (Figs. 2 and 3). Therefore, the N-terminal tetrapeptide
but not a single additional amino acid residue is responsible
for the elevated anti-HIV-1 and receptor binding activity of
LD78L.
3.4. E¡ect of CD26/dipeptidyl peptidase IV-mediated cleavage
of LD78L
We and others have shown that CD26/dipeptidyl peptidase
IV was able to process several chemokines such as SDF-1K
and SDF-1L [20], RANTES [22,23], MCP-2 [24], and MDC
[25]. CD26 cleaves the ¢rst two amino acids from the poly-
peptide carrying proline or alanine at the second position.
Since the N-terminal tetrapeptide of LD78L was APLA, a
possible substrate for CD26, we tested whether CD26-medi-
ated cleavage of LD78L a¡ects its anti-HIV-1 and receptor
binding activity. For this purpose, L cells expressing human
CD26 [20] were infected with the recombinant SeV expressing
LD78L, and the N-terminal sequence and the anti-HIV-1 and
receptor binding activities of LD78L produced in the presence
of CD26 were analyzed. Since the N-terminal amino acid
sequence of LD78L secreted from L cells expressing CD26
was LAADTP (Fig. 4A), the N-terminal dipeptide AP was
in fact removed by CD26. On the other hand, the dipeptide
was fully retained in the LD78L secreted from control L cells
without CD26 expression (Fig. 4A), indicating that LD78L is
a substrate of CD26. However, as shown in Fig. 4B and 4C,
LD78L produced in the presence of CD26 exhibited similar
levels of anti-HIV-1 and receptor binding activities to those of
LD78L produced in the absence of CD26, showing that the
N-terminal dipeptide AP is not responsible for the elevated
biological activity of LD78L.
4. Discussion
In this paper, we demonstrated that LD78L, a non-allelic
variant of MIP-1K, has higher anti-HIV-1 and receptor bind-
ing activities than MIP-1K. The N-terminal tetrapeptide
APLA of LD78L which is absent in MIP-1K appeared to be
Fig. 3. Receptor binding activity of MIP-1K (closed circles), LD78L
(closed triangles), LD78L-MIP-1K (open triangles), and Met-MIP-1K
(closed squares). Culture supernatants of CV-1 cells infected with
SeV carrying indicated chemokine genes were serially diluted and
assayed for their receptor binding activity as described in Section 2.
Data shown are representative of three independent experiments
with similar results.
Fig. 4. E¡ects of CD26-mediated cleavage of LD78L on its biologi-
cal activities. A: Proteins in culture supernatants of L cells express-
ing CD26 (L-CD26) or control L cells (L) infected with SeV carry-
ing the LD78L gene (LD78L) or the wild type SeV (SeV) were
analyzed by Western blotting using anti-MIP-1K antibody. The
N-terminal amino acid sequence of each protein band is shown.
B: Culture supernatants of L cells expressing CD26 (L-CD26) or
control L cells (L) infected with SeV carrying the LD78L gene
(LD78L) or the wild type SeV (SeV) were serially diluted and as-
sayed for their anti-HIV-1 activity. The levels of p24 antigen pro-
duction 3 days after infection are shown. C: Culture supernatants
of L cells expressing CD26 (open circles) or control L cells (closed
circles) infected with SeV carrying the LD78L gene were serially di-
luted and assayed for their receptor binding activity.
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responsible for the elevated anti-HIV-1 and receptor binding
activities. However, CD26-mediated removal of the N-termi-
nal dipeptide AP from LD78L did not alter its anti-HIV-1 and
receptor binding activities (Fig. 4), suggesting that dipeptide
LA next to the N-terminal dipeptide AP plays a critical role in
elevating biological activity of LD78L. An extensive mutagen-
ic study of the N-terminal portion of LD78L is now in prog-
ress to prove this hypothesis.
It is now clear that CD26-mediated cleavage of the N-ter-
minal dipeptide cause di¡erent impacts on di¡erent chemo-
kines. Anti-HIV-1 and chemotactic activities of SDF-1K and
SDF-1L are abolished by CD26-mediated cleavage [20]. In
contrast, RANTES lacking the N-terminal dipeptide loses
its ability to interact with CCR1 while it retains CCR5 inter-
action and thus could suppress replication of macrophage
tropic strains of HIV-1 [22,23]. The present study showed
that LD78L, another natural ligand of CCR5, also retained
its anti-HIV-1 and receptor binding activities after CD26-
mediated cleavage. In the human body, CD26 would facilitate
replication of HIV-1 with a T-cell line tropic phenotype, while
it has no e¡ect on HIV-1 with a macrophage tropic pheno-
type. It is possible that the level of CD26 expression may be
one of the key determinants for phenotypic shift of macro-
phage tropic HIV-1 to T-cell-line tropic HIV-1.
Recent studies showed that the levels of the production of
CC-chemokine including MIP-1K may play important roles in
HIV-1 transmission and disease progression to AIDS [26^30].
Since copy numbers of the LD78L gene were reported to vary
among individuals [13,14], it would be important to determine
the LD78L copy numbers of HIV-1-infected individuals with
di¡erent rates of disease progression as well as individuals
who were exposed to HIV-1 but still remain uninfected.
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